Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
95
BWAY Quote, Financials, Valuation and Earnings
Last price:
$19.42
Seasonality move
:
0.31%
Day range:
$18.31 - $19.70
52-week range:
$7.84 - $19.80
Dividend yield:
0%
P/E ratio:
61.45x
P/S ratio:
7.40x
P/B ratio:
5.22x
Volume:
35.5K
Avg. volume:
65.8K
1-year change:
106.72%
Market cap:
$366M
Revenue:
$41.2M
EPS (TTM):
$0.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BWAY
Brainsway Ltd.
|
$13M | $0.05 | 21.84% | -39.69% | $22.00 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | 10.1% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BWAY
Brainsway Ltd.
|
$19.37 | $22.00 | $366M | 61.45x | $0.00 | 0% | 7.40x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.21 | $2.50 | $3.4M | -- | $0.00 | 0% | 1.19x |
|
CGEN
Compugen Ltd.
|
$1.54 | $6.25 | $144M | 55.83x | $0.00 | 0% | 20.58x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$1.93 | $399.00 | $2.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BWAY
Brainsway Ltd.
|
8.79% | 2.419 | 2.37% | 2.92x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BWAY
Brainsway Ltd.
|
$10.2M | $1.3M | 9.49% | 10.23% | 9.27% | $41.2K |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
Brainsway Ltd. vs. Competitors
-
Which has Higher Returns BWAY or CANF?
Can-Fite BioPharma Ltd. has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of --. Brainsway Ltd.'s return on equity of 10.23% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BWAYBrainsway Ltd.75.19% $0.08 $76.8M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About BWAY or CANF?
Brainsway Ltd. has a consensus price target of $22.00, signalling upside risk potential of 13.58%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1068.77%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Brainsway Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Brainsway Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BWAYBrainsway Ltd.3 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is BWAY or CANF More Risky?
Brainsway Ltd. has a beta of 1.217, which suggesting that the stock is 21.701% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock BWAY or CANF?
Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BWAY or CANF?
Brainsway Ltd. quarterly revenues are $13.6M, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Brainsway Ltd.'s net income of $1.6M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Brainsway Ltd.'s price-to-earnings ratio is 61.45x while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 7.40x versus 1.19x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BWAYBrainsway Ltd.7.40x 61.45x $13.6M $1.6M CANFCan-Fite BioPharma Ltd.1.19x -- -- --
-
Which has Higher Returns BWAY or CGEN?
Compugen Ltd. has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of -369.06%. Brainsway Ltd.'s return on equity of 10.23% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital BWAYBrainsway Ltd.75.19% $0.08 $76.8M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About BWAY or CGEN?
Brainsway Ltd. has a consensus price target of $22.00, signalling upside risk potential of 13.58%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 305.84%. Given that Compugen Ltd. has higher upside potential than Brainsway Ltd., analysts believe Compugen Ltd. is more attractive than Brainsway Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BWAYBrainsway Ltd.3 0 0 CGENCompugen Ltd.4 0 0 -
Is BWAY or CGEN More Risky?
Brainsway Ltd. has a beta of 1.217, which suggesting that the stock is 21.701% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock BWAY or CGEN?
Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BWAY or CGEN?
Brainsway Ltd. quarterly revenues are $13.6M, which are larger than Compugen Ltd. quarterly revenues of $1.9M. Brainsway Ltd.'s net income of $1.6M is higher than Compugen Ltd.'s net income of -$7M. Notably, Brainsway Ltd.'s price-to-earnings ratio is 61.45x while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 7.40x versus 20.58x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BWAYBrainsway Ltd.7.40x 61.45x $13.6M $1.6M CGENCompugen Ltd.20.58x 55.83x $1.9M -$7M
-
Which has Higher Returns BWAY or NSRX?
Nasus Pharma has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of --. Brainsway Ltd.'s return on equity of 10.23% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BWAYBrainsway Ltd.75.19% $0.08 $76.8M NSRXNasus Pharma-- -- -- -
What do Analysts Say About BWAY or NSRX?
Brainsway Ltd. has a consensus price target of $22.00, signalling upside risk potential of 13.58%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Brainsway Ltd. has higher upside potential than Nasus Pharma, analysts believe Brainsway Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings BWAYBrainsway Ltd.3 0 0 NSRXNasus Pharma0 0 0 -
Is BWAY or NSRX More Risky?
Brainsway Ltd. has a beta of 1.217, which suggesting that the stock is 21.701% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BWAY or NSRX?
Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BWAY or NSRX?
Brainsway Ltd. quarterly revenues are $13.6M, which are larger than Nasus Pharma quarterly revenues of --. Brainsway Ltd.'s net income of $1.6M is higher than Nasus Pharma's net income of --. Notably, Brainsway Ltd.'s price-to-earnings ratio is 61.45x while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 7.40x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BWAYBrainsway Ltd.7.40x 61.45x $13.6M $1.6M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns BWAY or PHGE?
BiomX, Inc. has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of --. Brainsway Ltd.'s return on equity of 10.23% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital BWAYBrainsway Ltd.75.19% $0.08 $76.8M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About BWAY or PHGE?
Brainsway Ltd. has a consensus price target of $22.00, signalling upside risk potential of 13.58%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8449.22%. Given that BiomX, Inc. has higher upside potential than Brainsway Ltd., analysts believe BiomX, Inc. is more attractive than Brainsway Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BWAYBrainsway Ltd.3 0 0 PHGEBiomX, Inc.1 0 0 -
Is BWAY or PHGE More Risky?
Brainsway Ltd. has a beta of 1.217, which suggesting that the stock is 21.701% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock BWAY or PHGE?
Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BWAY or PHGE?
Brainsway Ltd. quarterly revenues are $13.6M, which are larger than BiomX, Inc. quarterly revenues of --. Brainsway Ltd.'s net income of $1.6M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Brainsway Ltd.'s price-to-earnings ratio is 61.45x while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 7.40x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BWAYBrainsway Ltd.7.40x 61.45x $13.6M $1.6M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
